In the present work, we investigated the “actionability” of these lung cancer-derived CRAF mutations with ERK pathway inhibitors (RAF and MEK inhibitors) and further determined the comparative efficacy of two classes of RAF inhibitors in targeting these mutations. The gene discussed is MAP2K7; the disease is lung carcinoma.